Latest biosimilar drugs news
FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
posted February 19th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Wezlana for Multiple Inflammatory Diseases
posted November 2nd
by modernClinician Editorial Team
by modernClinician Editorial Team
More Biosimilars Marketed in Germany, Switzerland Than U.S.
posted December 2nd
by modernClinician Editorial Team
by modernClinician Editorial Team
Biosimilars Could Cut Spending for Biologic Therapy in the U.S.
posted January 21st
by modernClinician Editorial Team
by modernClinician Editorial Team
Editor's Recommendations
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer 
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status 
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing Related Articles
FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections Monthly Specialist Briefings
Stay Connected
